MedPal AI (LSE:MPAL) Research & Development: £0.38 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MedPal AI Research & Development?

MedPal AI LSE:MPAL Research & Development is £0.38 Mil as of Feb. 2026. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MedPal AI's Research & Development for the six months ended in Feb. 2026 was £0.38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 was £0.38 Mil.

MedPal AI  (LSE:MPAL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MedPal AI Research & Development Related Terms

MedPal AI Research & Development Historical Data

* Premium members only.

The historical data trend for MedPal AI's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedPal AI Research & Development Chart

MedPal AI Annual Data
Trend Aug22 Aug23 Aug24 Aug25
Research & Development
0.00 0.00 0.00 0.00

MedPal AI Semi-Annual Data
Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.38

MedPal AI Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.38 Mil mean?
MedPal AI (LSE:MPAL) has a Research & Development of £0.38 Mil as of Feb. 2026. Research and development expense is the total cost for research and development activities. View historical data on MedPal AI and its competitors.
Is MedPal AI's Research & Development too high?
MedPal AI's current Research & Development is £0.38 Mil.
How does MedPal AI's Research & Development compare to VEEV and BTSG?
MedPal AI's Research & Development of £0.38 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MedPal AI and its competitors. MedPal AI's current Research & Development is £0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedPal AI stock overvalued right now?
MedPal AI (LSE:MPAL) has a current Research & Development of £0.38 Mil. The current Research & Development is £0.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MedPal AI (LSE:MPAL), the current Research & Development is £0.38 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedPal AI Business Description

Other Exchanges Z1N:Germany
Address 71 Queen Victoria Street, Floor 8, London, GBR, EC4V 4AY
MedPal AI PLC is a UK-based digital health and artificial intelligence company focused on the development and commercialisation of AI-enabled healthcare platforms.. Its platform aggregates data across devices and apps (including Apple Health, Fitbit, Garmin, and Google Fit) to deliver real-time, personalized health insights. The Company has two reportable segments, Software and Corporate.